Copyright
©The Author(s) 2004.
World J Gastroenterol. Mar 15, 2004; 10(6): 894-898
Published online Mar 15, 2004. doi: 10.3748/wjg.v10.i6.894
Published online Mar 15, 2004. doi: 10.3748/wjg.v10.i6.894
Table 1 Change in concentrations of laboratory data (mean ± SD)
| Laboratory Variable | Before therapy | 4 wk | 8 wk | 12 wk |
| AST (IU/L) | 29.9 ± 8.1 | 50.0 ± 36.3 | 46.6 ± 24.9 | 46.9 ± 28.3 |
| ALT(IU/L) | 31.1 ± 13.2 | 48.6 ± 35.2 | 57.0 ± 38.9 | 48.4 ± 42.5 |
| ALP (IU/L) | 285.0 ± 114.8 | 238.5 ± 88.4 | 200.6 ± 76.7a | 186.9 ± 76.2a |
| γ-GTP(IU/L) | 149.6 ± 143.0 | 147.0 ± 178.6 | 128.8 ± 128.1 | 125.2 ± 110.3 |
| LDH (IU/l) | 311.2 ± 46.7 | 318.4 ± 44.8 | 320.1 ± 59.9 | 324.6 ± 59.2 |
| TB (mg/dl) | 0.7 ± 0.7 | 0.4 ± 0.2 | 0.6 ± 0.4 | 0.6 ± 0.5 |
| IgG (mg/dl) | 1 431.4 ± 285.3 | - | - | 1 415.0 ± 316.1 |
| IgM (mg/dl) | 255.8 ± 85.9 | - | - | 192.9 ± 67.5a |
Table 2 Change in concentrations of serum lipids and apoproteins
| Varuables | Before | 4 wk | 8 wk | 12 wk |
| TC (mg/dL) | 206.3 ± 26.5 | 186.3 ± 22.9 | 189.9 ± 27.7a | 192.1 ± 30.1 |
| TG (mg/dL) | 126.0 ± 50.1 | 119.5 ± 76.2 | 102.8 ± 52.3 | 103.6 ± 53.0 |
| HDL-C (mg/dL) | 63.6 ± 11.3 | 63.8 ± 14.0 | 68.8 ± 12.6 | 69.3 ± 13.1 |
| LDL-C (mg/dL) | 115.7 ± 22.1 | 99.3 ± 29.3 | 105.6 ± 28.0 | 105.2 ± 25.1 |
| Apo A-I (mg/dL) | 159.0 ± 17.9 | 154.7 ± 19.4 | 158.3 ± 17.9 | 172.1 ± 24.3 |
| Apo A-II (mg/dL) | 31.6 ± 6.5 | 39.5 ± 7.0a | 40.7 ± 4.6a | 44.1 ± 4.9a |
| Apo B (mg/dL) | 95.1 ± 22.9 | 84.1 ± 31.4 | 81.0 ± 26.5 | 84.1 ± 23.1 |
| Apo C- II (mg/dL) | 3.9 ± 1.7 | 4.6 ± 2.0a | 4.2 ± 1.6 | 4.5 ± 1.5a |
| Apo C-III (mg/dL) | 9.7 ± 3.8 | 9.5 ± 4.2 | 8.9 ± 2.9 | 9.8 ± 3.6 |
| Apo E (mg/dL) | 4.3 ± 1.0 | 4.3 ± 0.8 | 4.4 ± 0.8 | 4.6 ± 0.9 |
Table 3 Rate of change in the valuables between AMA-reduced group and AMA-unchanged group
| Factors | AMA-reduced group | AMA-unchanged group | t-test |
| ALT (IU/L) | 61.6 ± 124.81 | 52.0 ± 109.2 | 0.905 |
| ALP (IU/L) | -33.4 ± 24.8 | -33.8 ± 16.0 | 0.978 |
| γ-GTP (IU/L) | -2.8 ± 73.4 | -5.3 ± 39.8 | 0.950 |
| IgM (mg/dL) | -35.4 ± 0.6 | -7.1 ± 11.8 | 0.010 |
| Apo A-II (mg/dL) | 52.0 ± 17.3 | 37.4 ± 38.6 | 0.573 |
| Apo C-II (mg/dL) | 29.5 ± 13.8 | 10.6 ± 10.1 | 0.089 |
- Citation: Dohmen K, Mizuta T, Nakamuta M, Shimohashi N, Ishibashi H, Yamamoto K. Fenofibrate for patients with asymptomatic primary biliary cirrhosis. World J Gastroenterol 2004; 10(6): 894-898
- URL: https://www.wjgnet.com/1007-9327/full/v10/i6/894.htm
- DOI: https://dx.doi.org/10.3748/wjg.v10.i6.894